B-cell-depleting induction therapy and acute cellular rejection.
Clatworthy
Menna R
MR
Watson
Christopher J E
CJ
Plotnek
Gemma
G
Bardsley
Vicky
V
Chaudhry
Afzal N
AN
Bradley
J Andrew
JA
Smith
Kenneth G C
KG
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes; D016207:Cytokines / Q000097:blood; D000077561:Daclizumab; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion; D000069283:Rituximab; D019172:Transplantation Conditioning; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000077561:Daclizumab